FT. LEE, N.J.--(BUSINESS WIRE)--Karen Bien, director, Business Technology, in Pfizer’s Acquisition, Collaboration and Divestiture team, has been elected to the board of directors of SAFE-BioPharma Association, the strategic non-profit collaboration that developed and manages the global SAFE-BioPharma® digital identity and digital signature standard for the life science and healthcare sectors. The association’s members include most of the world’s largest biopharmaceutical companies.
In the volunteer board position, Ms. Bien will participate in leading SAFE-BioPharma’s global expansion involving biopharmaceutical industry partners in governments, research institutions and the U.S. healthcare system.
Ms. Bien has extensive leadership experience across the pharmaceutical and healthcare industries. At Pfizer, she leads a team that provides technical services and support required for external alliances. She previously held a variety of compliance, continuous improvement and related roles at Wyeth Pharmaceuticals (now Pfizer), Siemens Medical Systems and Innovex.
“We are fortunate to have Karen Bien as a member of the SAFE-BioPharma Board of Directors,” said Mollie Shields-Uehling, president and CEO, SAFE-BioPharma Association. “Karen’s expertise in applying technology to advance collaborative communities within the biopharmaceutical arena will be valuable to the governance of the standard.”
Ms. Bien holds an MBA from Eastern University and B.S. degrees from Lebanon Valley College and Thomas Jefferson University. She is a Certified Software Quality Engineer (CSQE), holds Green Belt certification and completed the Lean Six Sigma Certificate Program at Villanova University.
SAFE-BioPharma
For more information on the SAFE-BioPharma standard for digital identity and digital signatures used in life science and healthcare settings, visit http://www.safe-biopharma.org.
SAFE-BioPharma® is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association.